Moreover, other types of RIPK1 inhibitors DNL747 and DNL758 were developed by Sanofi and Denali, of which DNL747 is a blood–brain barrier (BBB) penetrable drug and has entered into clinical trials for the treatment of AD (NCT03757325) and ALS (NCT03757351), whereas DNL758 is unable to penetrate the BBB and is therefore used in the treatment for SIRS-associated diseases [199]. This evidence concerns the gene RIPK1 and amyotrophic lateral sclerosis.